The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PBRM1 genomic alterations as a predictive biomarker to immune checkpoint inhibitors (ICI) and/or anti-angiogenic therapies (anti-VEGF) in metastatic renal cell carcinoma (mRCC): A systematic review and meta-analysis.
 
Lucio Ghiglione
No Relationships to Disclose
 
Laia Fernandez-Mañas
No Relationships to Disclose
 
Laura Ferrer-Mileo
No Relationships to Disclose
 
Caterina Aversa
No Relationships to Disclose
 
Marta Garcia de Herreros
No Relationships to Disclose
 
Juan Carlos Laguna
No Relationships to Disclose
 
Teresa Gorria
No Relationships to Disclose
 
Mercedes Marin
No Relationships to Disclose
 
Natalia Jiménez
No Relationships to Disclose
 
Aleix Prat
Employment - Novartis (I)
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Joan Maurel
Consulting or Advisory Role - AstraZeneca; Pierre Fabre; Sanofi; Servier; Shire; Sirtex Medical
Research Funding - Amgen; Biocartis; Biocartis; Incyte; Merck Serono; NanoString Technologies; Roche
Travel, Accommodations, Expenses - Amgen
Other Relationship - Advance Medical/Teladoc Health; AstraZeneca; Bayer; Cancer Expert Now; Fundación Clínica Universitaria; Pierre Fabre; Roche; Sanofi Pasteur; SERVIER; Shire; Sirtex Medical
 
Begona Mellado
Consulting or Advisory Role - Amgen (I); Astellas Pharma; AstraZeneca Spain; Bayer; Janssen; Pfizer; Pfizer (I); Roche; Roche (I)
Research Funding - Bayer; Janssen; Roche
Travel, Accommodations, Expenses - Janssen-Cilag; Roche (I)
 
Oscar Reig
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Sanofi
Travel, Accommodations, Expenses - Ipsen